

# Robert A Byrne Mb Bch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/107560/publications.pdf>

Version: 2024-02-01

327  
papers

32,172  
citations

6613

79  
h-index

4548

171  
g-index

363  
all docs

363  
docs citations

363  
times ranked

21825  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Cardiovascular Revascularization Medicine, 2022, 34, 17-24.	0.8	9
2	Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. Cardiovascular Revascularization Medicine, 2022, 36, 99-106.	0.8	3
3	A prospective trial of a novel <scp>low-dose paclitaxel-coated</scp> balloon therapy in patients with restenosis in <scp>drug-eluting</scp> coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent <scp>In-stent</scp> REstenosis <scp>3A</scp> (ISAR-DESIRE 3A). Catheterization and Cardiovascular Interventions, 2022, 99, 754-762.	1.7	2
4	OUP accepted manuscript. European Heart Journal, 2022, , .	2.2	1
5	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. EuroIntervention, 2022, 17, 1348-1351.	3.2	3
6	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, e023493.	3.7	5
7	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2021, 42, 308-319.	2.2	90
8	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
9	Impact of Calcified Lesion Complexity on the Success of Percutaneous Coronary Intervention With Upfront High-Speed Rotational Atherectomy or Modified Balloons - A Subgroup-Analysis From the Randomized PREPARE-CALC Trial. Cardiovascular Revascularization Medicine, 2021, 33, 26-31.	0.8	4
10	European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. European Heart Journal, 2021, 42, 1545-1553.	2.2	32
11	Dynamic left ventricular outflow tract gradient resulting from Takotsubo cardiomyopathy ameliorated by intra-aortic balloon pump counterpulsation: a case report. European Heart Journal - Case Reports, 2021, 5, ytab082.	0.6	4
12	Durable or Biodegradable Polymer Stent Coatings. Circulation, 2021, 143, 1092-1094.	1.6	0
13	Choice of Primary Endpoint for Trials Comparing Balloon Angioplasty and Stenting. JACC: Cardiovascular Interventions, 2021, 14, 709.	2.9	0
14	Biodegradable- Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2021, 14, 649-652.	2.9	1
15	Optical Coherence Tomography Assessment in Patients Treated With Rotational Atherectomy Versus Modified Balloons. Circulation: Cardiovascular Interventions, 2021, 14, e009819.	3.9	19
16	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. Clinical Research in Cardiology, 2021, 110, 1586-1598.	3.3	7
17	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	3.7	5
18	Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial. International Journal of Cardiovascular Imaging, 2021, 37, 2815-2826.	1.5	1

#	ARTICLE	IF	CITATIONS
19	Super high-pressure balloon versus scoring balloon to prepare severely calcified coronary lesions: the ISAR-CALC randomised trial. <i>EuroIntervention</i> , 2021, 17, 481-488.	3.2	28
20	Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 772-795.	4.1	24
21	Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. <i>Inflammation Research</i> , 2021, 70, 1075-1087.	4.0	12
22	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. <i>Journal of the American Heart Association</i> , 2021, 10, e018828.	3.7	4
23	Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once. <i>Lancet, The</i> , 2021, , .	13.7	0
24	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 277-285.	0.8	0
25	Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 361-366.	0.8	4
26	Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 225-231.	0.6	0
27	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
28	Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials. <i>American Heart Journal</i> , 2020, 219, 109-116.	2.7	6
29	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	1.8	15
30	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1008-1015.	1.7	4
31	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	2.9	13
32	Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 857-862.	1.7	1
33	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1392-1393.	2.8	0
34	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.8	35
35	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 74, 584-590.	0.6	0
36	Impact of Lesion Preparation Technique on Side Branch Compromise in Calcified Coronary Bifurcations: A Subgroup Analysis of the PREPARE-CALC Trial. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-8.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Implementing the new European Regulations on medical devicesâ€”clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology. <i>European Heart Journal</i> , 2020, 41, 2589-2596.	2.2	37
38	Polymer-Free Drug-Eluting Stents. <i>Circulation</i> , 2020, 141, 2064-2066.	1.6	5
39	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. <i>International Journal of Cardiology</i> , 2020, 312, 42-47.	1.7	4
40	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2020, 76, 146-158.	2.8	49
41	Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008657.	3.9	11
42	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	2.8	70
43	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest â€” A propensity score-matched analysis. <i>PLoS ONE</i> , 2020, 15, e0218634.	2.5	7
44	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
45	Aspirin for secondary prevention of cardiovascular disease. <i>Lancet, The</i> , 2020, 395, 1462-1463.	13.7	13
46	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. <i>EuroIntervention</i> , 2020, 15, 1451-1457.	3.2	14
47	Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. <i>EuroIntervention</i> , 2020, 15, 1190-1198.	3.2	17
48	The year in review: coronary interventions. <i>EuroIntervention</i> , 2020, 15, 1534-1547.	3.2	0
49	Occupational radiation exposure in interventional cardiology â€” time for further action. <i>EuroIntervention</i> , 2020, 16, 613-616.	3.2	3
50	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
51	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	402
52	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society Europe. 2019, 21, 192-193.	1.7	209
53	TCT-26 Predictors of Bailout Rotational Atherectomy in Patients With Complex Calcified Coronary Artery Disease: A Pooled Analysis From the Randomized ROTAXUS and PREPARE-CALC Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, B26.	2.8	1
54	TCT-283 10-Year Clinical Outcomes From a Trial of 3 Limus-Eluting Stents With Different Polymer Coatings in Diabetic Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B282.	2.8	0

#	ARTICLE	IF	CITATIONS
55	TCT-661 Angiographic Results of Everolimus-Eluting Stents for the Treatment of In-Stent Restenosis. Journal of the American College of Cardiology, 2019, 74, B649.	2.8	0
56	TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial. Journal of the American College of Cardiology, 2019, 74, B11.	2.8	0
57	Shedding Light on the Optimal Management of Patients Presenting With Transient ST-Segment Elevation. JACC: Cardiovascular Interventions, 2019, 12, 2283-2285.	2.9	0
58	Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. European Heart Journal, 2019, 40, 2566-2584.	2.2	189
59	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
60	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
61	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet, The, 2019, 393, 2503-2510.	13.7	166
62	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. Clinical Research in Cardiology, 2019, 108, 1059-1068.	3.3	13
63	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 2019, 115, 1512-1518.	3.8	15
64	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. Circulation, 2019, 139, 325-333.	1.6	97
65	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. Catheterization and Cardiovascular Interventions, 2019, 93, 912-920.	1.7	22
66	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. European Heart Journal, 2019, 40, 167-176.	2.2	40
67	Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. EuroIntervention, 2019, 15, 615-622.	3.2	7
68	Omission of aspirin after ACS or stenting in patients with oral anticoagulation “why have the goalposts moved?”. EuroIntervention, 2019, 14, e1793-e1795.	3.2	5
69	Medical device regulation in Europe “what is changing and how can I become more involved?”. EuroIntervention, 2019, 15, 647-649.	3.2	7
70	2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2019, 14, 1435-1534.	3.2	367
71	Patient focus in interventional cardiology: proceedings of the 2018 summit of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) “Nice, France, 20-21 June 2018. EuroIntervention, 2019, 14, 1720-1723.	3.2	2
72	Markers of Reperfusion and Long-Term (8-Year) Prognosis after Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 39-46.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.8	2
74	Incidencia y predictores de la reestenosis recurrente tras angioplastia con balón farmacológico en reestenosis de stents farmacológicos: proyecto cooperativo ICARUS. Revista Española De Cardiología, 2018, 71, 620-627.	1.2	14
75	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	2.2	22
76	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Revista Española De Cardiología (English Ed ), 2018, 71, 42.	0.6	29
77	Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. European Heart Journal Cardiovascular Imaging, 2018, 19, 1294-1301.	1.2	9
78	Current Use of Intracoronary Imaging in Interventional Practice—Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. Circulation Journal, 2018, 82, 1360-1368.	1.6	31
79	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. Journal of the American College of Cardiology, 2018, 71, 1973-1982.	2.8	52
80	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. International Journal of Cardiology, 2018, 258, 42-49.	1.7	12
81	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
82	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. European Heart Journal, 2018, 39, 1591-1601.	2.2	45
83	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
84	Incidence and predictors of recurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drug-eluting Stent: The ICARUS Cooperation. Revista Española De Cardiología (English) 2018, 71, 1000-1006.	0.6	10
85	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2018, 19, 480-486.	0.8	5
86	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. International Journal of Cardiology, 2018, 252, 57-62.	1.7	16
87	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e006752.	3.9	32
88	Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. Circulation: Cardiovascular Interventions, 2018, 11, e007239.	3.9	4
89	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. Circulation: Cardiovascular Interventions, 2018, 11, e006074.	3.9	12
90	Endovascular stenting in femoropopliteal arteries. Lancet, The, 2018, 392, 1491-1493.	13.7	5



#	ARTICLE	IF	CITATIONS
91	High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007415.	3.9	164
92	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>European Heart Journal</i> , 2018, 39, 3281-3300.	2.2	431
93	Neoatherosclerosis in Patients With Coronary Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1340-1350.	2.9	35
94	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 13, 1565-1573.	3.2	35
95	Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 14, 224-231.	3.2	16
96	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. <i>EuroIntervention</i> , 2018, 14, e1227-e1235.	3.2	13
97	Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy alone: a meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data. <i>EuroIntervention</i> , 2018, 14, 857-867.	3.2	8
98	Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology. <i>EuroIntervention</i> , 2018, 14, 708-715.	3.2	8
99	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>EuroIntervention</i> , 2018, 13, 1574-1586.	3.2	35
100	What interventionalists can learn from the aviation industry. <i>EuroIntervention</i> , 2018, 13, 1977-1979.	3.2	3
101	The discovery of X-rays, the fate of atomic bomb survivors, and the impact on modern interventional cardiology. <i>EuroIntervention</i> , 2018, 14, 129-131.	3.2	2
102	Current use of intracoronary imaging in interventional practice – Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>EuroIntervention</i> , 2018, 14, e475-e484.	3.2	87
103	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>EuroIntervention</i> , 2018, 14, 656-677.	3.2	92
104	In-Stent Restenosis. , 2018, , 469-481.		0
105	Evidence-based medicine, transparency and reproducibility in research, and challenges for peer review. <i>EuroIntervention</i> , 2018, 13, 1615-1617.	3.2	3
106	The use and impact of clinical practice guidelines in interventional cardiology. <i>EuroIntervention</i> , 2018, 14, 607-608.	3.2	0
107	The ESC Congress 2018 and the legacy of Eugene Braunwald. <i>EuroIntervention</i> , 2018, 14, 1067-1068.	3.2	0
108	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141.	1.7	120

#	ARTICLE	IF	CITATIONS
109	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	63
110	Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1222-1229.	2.9	26
111	An FFR <sub>CT</sub> diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: one-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FFR <sub>CT</sub> : Outcome) Tj ETQq1 1 0.784314 11 BT /Over	2.3	11
112	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. <i>American Heart Journal</i> , 2017, 187, 104-111.	2.7	11
113	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2330-2344.	2.8	117
114	Biodegradable polymer drug-eluting stents: caveat emptor. <i>Lancet, The</i> , 2017, 390, 1814-1816.	13.7	0
115	Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis. <i>JAMA Cardiology</i> , 2017, 2, 1079.	6.1	99
116	Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis. <i>Circulation</i> , 2017, 136, 1007-1021.	1.6	200
117	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery	2.2	335
118	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 408-417.	1.4	160
119	Coronary balloon angioplasty, stents, and scaffolds. <i>Lancet, The</i> , 2017, 390, 781-792.	13.7	179
120	Transfemoral Approach for Coronary Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2269-2279.	2.9	32
121	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	2.8	51
122	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1332-1340.	2.9	98
123	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1-10.	1.7	4
124	Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 367-374.	1.7	7
125	Markedly different tissue types on optical coherence tomography imaging in a patient with multiple lesion drug-eluting stent in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E181-E184.	1.7	3
126	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2548-2556.	2.9	8



#	ARTICLE	IF	CITATIONS
127	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1989-1999.	3.4	26
128	Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOLving Stent Technology. <i>Interventional Cardiology Review</i> , 2017, 13, 40.	1.6	2
129	PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent. <i>Interventional Cardiology Review</i> , 2017, 12, 13.	1.6	7
130	Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. <i>EuroIntervention</i> , 2017, 12, 2132-2139.	3.2	13
131	Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. <i>EuroIntervention</i> , 2017, 13, 483-489.	3.2	17
132	Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2017, 13, 986-993.	3.2	5
133	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. <i>EuroIntervention</i> , 2017, 13, 962-969.	3.2	6
134	Acute myocardial infarction in a young endurance athlete caused by probable plaque erosion. <i>EuroIntervention</i> , 2017, 13, e246-e247.	3.2	1
135	State of the art: coronary artery stents “past, present and future. <i>EuroIntervention</i> , 2017, 13, 706-716.	3.2	63
136	Regulation of coronary stents “physicians as stakeholders. <i>EuroIntervention</i> , 2017, 12, 1679-1680.	3.2	1
137	40 years of angioplasty “remembering patients and pioneers. <i>EuroIntervention</i> , 2017, 12, 2041-2043.	3.2	2
138	Fallout from the ORBITA trial “is angioplasty in a spin?. <i>EuroIntervention</i> , 2017, 13, 1253-1254.	3.2	3
139	State of the art: 40 years of percutaneous cardiac intervention. <i>EuroIntervention</i> , 2017, 13, 621-624.	3.2	5
140	Continuing medical education and sponsorship by the healthcare industry “new opportunities and challenges. <i>EuroIntervention</i> , 2017, 13, e137-e138.	3.2	1
141	EuroPCR 2017, late-breaking clinical trials and <i>EuroIntervention</i> . <i>EuroIntervention</i> , 2017, 13, e499-e502.	3.2	0
142	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. <i>Journal of Thoracic Disease</i> , 2016, 8, E417-E423.	1.4	6
143	Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the <scp>ISAR-ABSORB</scp> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 822-829.	1.7	28
144	Temporal Trends in Strut-Level Optical Coherence Tomography Evaluation of Coronary Stent Coverage. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 1083-1093.	1.7	14

#	ARTICLE	IF	CITATIONS
145	Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	3.7	7
146	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. American Heart Journal, 2016, 177, 9-16.	2.7	15
147	Arzones vasculares bioabsorbibles en lesiones de bifurcaci3n coronaria: solo en manos expertas. Revista Espanola De Cardiologia, 2016, 69, 543-546.	1.2	2
148	Bioresorbable Vascular Scaffolds in Coronary Bifurcation Lesions: Only in Expert Hands. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 543-546.	0.6	1
149	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clinical Research in Cardiology, 2016, 105, 575-584.	3.3	18
150	Drug coated balloon angioplasty in the treatment of peripheral artery disease. Expert Review of Medical Devices, 2016, 13, 569-582.	2.8	8
151	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Cardiovascular Diabetology, 2016, 15, 124.	6.8	13
152	Bifurcation intervention with a two-stent strategy: can one size fit all?. European Heart Journal, 2016, 37, 3406-3408.	2.2	4
153	Drug-Coated Balloon Versus Plain Balloon4Angioplasty for the Treatment of4Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1731-1742.	2.9	80
154	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	3
155	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 2259-2268.	2.8	88
156	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 435-445.	2.8	313
157	TCT-414 Two-year outcomes of patients with acute coronary syndrome versus stable coronary disease undergoing bioresorbable scaffold implantation. Journal of the American College of Cardiology, 2016, 68, B168.	2.8	0
158	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Scientific Reports, 2016, 6, 33054.	3.3	14
159	Disappearing scaffolds, dissolving expectations. Lancet, The, 2016, 388, 2451-2452.	13.7	5
160	Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. Catheterization and Cardiovascular Interventions, 2016, 88, 184-190.	1.7	6
161	Bioresorbable Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1228-1230.	2.9	3
162	Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream?. European Heart Journal, 2016, 37, 241-244.	2.2	11

#	ARTICLE	IF	CITATIONS
163	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	2.2	147
164	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2016, 387, 537-544.	13.7	317
165	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , 2016, 117, 532-538.	1.6	17
166	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 784-792.	2.9	52
167	Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. <i>Aids</i> , 2016, 30, 1413-1421.	2.2	12
168	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. <i>EuroIntervention</i> , 2016, 12, 103-111.	3.2	88
169	Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. <i>EuroIntervention</i> , 2016, 12, 112-118.	3.2	4
170	Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting. <i>EuroIntervention</i> , 2016, 11, 1020-1026.	3.2	11
171	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. <i>EuroIntervention</i> , 2016, 11, 1372-137.	3.2	60
172	Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. <i>EuroIntervention</i> , 2016, 12, 1154-1163.	3.2	12
173	Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. <i>EuroIntervention</i> , 2016, 12, e137-e143.	3.2	6
174	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. <i>EuroIntervention</i> , 2016, 11, e1275-e1282.	3.2	0
175	Peer review at <i>EuroIntervention</i> – a rough guide and an expression of thanks. <i>EuroIntervention</i> , 2016, 12, 1197-1199.	3.2	1
176	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. <i>European Heart Journal</i> , 2015, 36, 2147-2159.	2.2	362
177	Drug-Coated Balloon Angioplasty for De Novo Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 2010-2012.	2.9	7
178	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2266-2267.	2.8	0
179	Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2315-2323.	2.8	164
180	Bioresorbable Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 198-200.	2.9	21

#	ARTICLE	IF	CITATIONS
181	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
182	Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. <i>European Heart Journal</i> , 2015, 36, 94-99.	2.2	98
183	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 877-884.	2.9	85
184	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	2.2	187
185	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2015, 104, 887-901.	3.3	24
186	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	2.8	401
187	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 156-162.	0.8	26
188	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1308-1315.	3.4	13
189	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÅ¼ntzig Lecture ESC 2014. <i>European Heart Journal</i> , 2015, 36, 3320-3331.	2.2	441
190	Rationale and design of the Prospective Longitudinal Trial of FFRCT: Outcome and Resource IMpacts study. <i>American Heart Journal</i> , 2015, 170, 438-446.e44.	2.7	15
191	Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1928-1936.	0.7	18
192	Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. <i>European Heart Journal</i> , 2015, 36, 1212-1215.	2.2	3
193	Bioresorbable Vascular Scaffolds “Will Promise Become Reality?”. <i>New England Journal of Medicine</i> , 2015, 373, 1969-1971.	27.0	10
194	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1089-1090.	2.8	3
195	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , 2015, 386, 655-664.	13.7	261
196	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR <sub>CT</sub> : outcome and resource impacts study. <i>European Heart Journal</i> , 2015, 36, 3359-3367.	2.2	467
197	Biodegradable polymer drug-eluting stents: ready for US prime time?. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 323-325.	0.8	0
198	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015, 10, 1425-1431.	3.2	20

#	ARTICLE	IF	CITATIONS
199	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	3.2	21
200	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention, 2015, 11, 68-74.	3.2	48
201	European expert consensus on rotational atherectomy. EuroIntervention, 2015, 11, 30-36.	3.2	247
202	Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) â€“ follow the â€œright cusp ruleâ€•. EuroIntervention, 2015, 11, 840-842.	3.2	9
203	Pathological aspects of bioresorbable stent implantation. EuroIntervention, 2015, 11, V159-V165.	3.2	15
204	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention, 2015, 11, 196-203.	3.2	38
205	Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tt 5	3.2	1
206	Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart Journal, 2014, 66, 345-349.	0.5	9
207	Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. European Heart Journal Cardiovascular Imaging, 2014, 15, 216-225.	1.2	41
208	Impact of in-hospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	2.7	9
209	Aspiration thrombectomy in patients undergoing primary angioplasty: Totality of data to 2013. Catheterization and Cardiovascular Interventions, 2014, 84, 973-977.	1.7	37
210	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheterization and Cardiovascular Interventions, 2014, 83, 182-189.	1.7	29
211	Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture. JAMA - Journal of the American Medical Association, 2014, 312, 1981.	7.4	162
212	Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. Circulation: Cardiovascular Interventions, 2014, 7, 207-215.	3.9	43
213	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. Cardiovascular Revascularization Medicine, 2014, 15, 69-75.	0.8	12
214	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. International Journal of Cardiovascular Imaging, 2014, 30, 495-504.	1.5	33
215	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2014, 7, 29-36.	2.9	44
216	Current Treatment of In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 2659-2673.	2.8	443

#	ARTICLE	IF	CITATIONS
217	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimenâ€”Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. American Heart Journal, 2014, 167, 459-465.e1.	2.7	19
218	Incidence and predictors of restenosis after coronary stenting in 10â€¦004 patients with surveillance angiography. Heart, 2014, 100, 153-159.	2.9	351
219	Drug-coated balloon therapy in coronary and peripheral artery disease. Nature Reviews Cardiology, 2014, 11, 13-23.	13.7	180
220	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. International Journal of Cardiology, 2014, 175, 484-491.	1.7	10
221	Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opinion on Pharmacotherapy, 2014, 15, 2155-2171.	1.8	23
222	TCT- 460 Bivalirudin versus heparin during percutaneous coronary intervention: aâ€”meta-analysis of randomized trials. Journal of the American College of Cardiology, 2014, 64, B135.	2.8	0
223	Drug-eluting stent trials: too much non-inferiority, too little progress?. Lancet, The, 2014, 383, 386-388.	13.7	12
224	Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. EuroIntervention, 2014, 10, 83-89.	3.2	3
225	Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site â€” CLOSURE device versus manual compression (ISAR-CLOSURE) trial. EuroIntervention, 2014, 10, 198-203.	3.2	8
226	PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort: PRESTIGE. European Heart Journal, 2014, 35, 2128-9.	2.2	6
227	Fiveâ€”year clinical outcomes of a polymerâ€”free sirolimusâ€”eluting stent versus a permanent polymer paclitaxelâ€”eluting stent: Final results of the intracoronary stenting and angiographic restenosis â€” test equivalence between two drugâ€”eluting stents (ISARâ€”TEST) trial. Catheterization and Cardiovascular Interventions, 2013, 81, E23-8.	1.7	47
228	Unmet Aspirations â€” Where To Now for Catheter Thrombectomy?. New England Journal of Medicine, 2013, 369, 1649-1650.	27.0	8
229	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 2075-2082.	2.8	69
230	Prognostic value of coronary computed tomography angiography during 5 years of follow-up in patients with suspected coronary artery disease. European Heart Journal, 2013, 34, 3277-3285.	2.2	174
231	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet, The, 2013, 381, 461-467.	13.7	347
232	Sex-related effectiveness of bivalirudin versus abciximab and heparin in nonâ€”ST-segment elevation myocardial infarction. American Heart Journal, 2013, 165, 537-543.	2.7	13
233	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2013, 6, 1267-1274.	2.9	286
234	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. American Heart Journal, 2013, 166, 534-540.	2.7	42



#	ARTICLE	IF	CITATIONS
235	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. International Journal of Cardiology, 2013, 168, 5162-5166.	1.7	29
236	Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. Cardiovascular Revascularization Medicine, 2013, 14, 84-89.	0.8	20
237	The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147) - a potential novel target in atherothrombosis prevention?. Thrombosis Research, 2013, 131, 474-480.	1.7	21
238	Polymer-free Sirolimus-eluting Versus Polymer-based Paclitaxel-eluting Stents: An Individual Patient Data Analysis of Randomized Trials. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 435-442.	0.6	2
239	Stents liberadores de rapamicina sin pol�mero frente a stents liberadores de paclitaxel con pol�mero: un an�lisis de datos de pacientes procedentes de ensayos aleatorizados. Revista Espanola De Cardiologia, 2013, 66, 435-442.	1.2	11
240	Comparative efficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. American Heart Journal, 2013, 165, 80-86.	2.7	33
241	Vascular access and closure in coronary angiography and percutaneous intervention. Nature Reviews Cardiology, 2013, 10, 27-40.	13.7	44
242	Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1376-1383.	2.4	70
243	Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis. Journal of Biomaterials Applications, 2013, 27, 717-726.	2.4	17
244	Second� versus first� generation ��limus��eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR��TEST��4 trial. Catheterization and Cardiovascular Interventions, 2013, 82, E769-76.	1.7	13
245	Treatment of coronary drug-eluting stent restenosis: a journey back to the future?. Expert Review of Medical Devices, 2013, 10, 423-427.	2.8	0
246	How should I treat a restenosis after superficial femoral artery stenting?. EuroIntervention, 2013, 8, 1342-1345.	3.2	2
247	Polymer coatings on drug-eluting stents: Samson��s hair and Achilles�� heel?. EuroIntervention, 2013, 9, 302-305.	3.2	19
248	Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention, 2013, 9, 797-802.	3.2	47
249	Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. EuroIntervention, 2013, 9, 412-413.	3.2	1
250	No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2012, 5, 82-88.	3.9	37
251	Response to Letter Regarding Article, ��Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention��. Circulation, 2012, 126, .	1.6	0
252	Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. Circulation: Cardiovascular Interventions, 2012, 5, 582-589.	3.9	117

#	ARTICLE	IF	CITATIONS
253	Clinical Use of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5224-5239.	1.9	28
254	Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. <i>BMJ</i> , The, 2012, 345, e5170-e5170.	6.0	196
255	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 429-432.	1.5	12
256	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1424-1431.	1.6	207
257	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , 2012, 33, 1214-1222.	2.2	359
258	The battle against stent thrombosisâ€”to protect and to serve. <i>Lancet</i> , The, 2012, 380, 1365-1367.	13.7	0
259	Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 381-391.	3.9	43
260	A case where the principle of â€œone question, one answerâ€•may work better. <i>American Heart Journal</i> , 2012, 163, 133-135.	2.7	0
261	TCT-353 Long-Term Outcomes of Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents in Patients with Diabetes: A Pooled Analysis of Individual Patient Data from the ISAR-TEST 4 and LEADERS Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2012, 60, B100.	2.8	0
262	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2012, 33, 3078-3087.	2.2	115
263	Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. <i>Journal of Experimental Medicine</i> , 2012, 209, 819-835.	8.5	1,441
264	Prognostic value of coronary computed tomographic angiography in patients with arterial hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 641-650.	1.5	4
265	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2012, 101, 461-467.	3.3	46
266	AS-095 Differential Vascular Healing Patterns with Rapid Absorption Biodegradable Polymer Sirolimus-Eluting Stents versus Durable Polymer Everolimus-Eluting Stents. <i>American Journal of Cardiology</i> , 2012, 109, S47-S48.	1.6	0
267	Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. <i>EuroIntervention</i> , 2012, 8, 752-759.	3.2	24
268	Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. <i>Minerva Cardioangiologica</i> , 2012, 60, 473-89.	1.2	33
269	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 999-1014.	1.5	4
270	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>European Heart Journal</i> , 2011, 32, 1605-1613.	2.2	174

#	ARTICLE	IF	CITATIONS
271	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 1325-1331.	2.8	131
272	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.. JACC: Cardiovascular Interventions, 2011, 4, 1129-1132.	2.9	15
273	Abciximab and Heparin versus Bivalirudin for Non-“ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2011, 365, 1980-1989.	27.0	285
274	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. American Heart Journal, 2011, 161, 68-75.	2.7	90
275	Effects of verbal suggestion on coronary arteries: Results of a randomized controlled experimental investigation during coronary angiography. American Heart Journal, 2011, 162, 507-511.	2.7	24
276	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. Clinica Chimica Acta, 2011, 412, 1350-1356.	1.1	16
277	High platelet reactivity and clinical outcome “ Fact and fiction. Thrombosis and Haemostasis, 2011, 106, 191-202.	3.4	63
278	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet, The, 2011, 378, 1071-1078.	13.7	164
279	Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thrombosis and Haemostasis, 2011, 105, 864-872.	3.4	66
280	Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and Haemostasis, 2011, 106, 555-558.	3.4	7
281	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clinical Research in Cardiology, 2011, 100, 691-699.	3.3	7
282	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. Catheterization and Cardiovascular Interventions, 2011, 77, 494-501.	1.7	17
283	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. Catheterization and Cardiovascular Interventions, 2011, 78, 161-166.	1.7	13
284	New Roads, New Ruts. JACC: Cardiovascular Interventions, 2011, 4, 165-167.	2.9	20
285	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. Current Drug Targets, 2011, 12, 1836-1847.	2.1	11
286	Everolimus-Eluting Versus Sirolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2011, 4, 371-377.	3.9	55
287	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. Circulation, 2011, 124, 624-632.	1.6	126
288	Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention, 2011, 7, 730-737.	3.2	77

#	ARTICLE	IF	CITATIONS
289	Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice?. <i>EuroIntervention</i> , 2011, 7, K47-K52.	3.2	8
290	Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial. <i>Interventional Cardiology</i> , 2010, 2, 267-273.	0.0	2
291	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	3.4	28
292	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 27-34.	1.2	23
293	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , 2010, 99, 13-19.	3.3	10
294	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1212-1217.	1.6	53
295	Retrograde salvage approach to treat tibial artery perforation during attempted revascularization of a chronically occluded artery. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 741-745.	1.7	3
296	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2383-2389.	2.8	380
297	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2710-2716.	2.8	192
298	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2536-2543.	2.8	108
299	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. <i>American Heart Journal</i> , 2010, 160, 355-361.	2.7	20
300	Pharmacological prevention and management of restenosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1855-1872.	1.8	4
301	The importance of preclinical research in contemporary interventional cardiology. <i>EuroIntervention</i> , 2010, 6, 19-23.	3.2	10
302	Primary Percutaneous Coronary Intervention. , 2010, , 65-77.		0
303	Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. <i>Heart</i> , 2009, 95, 1489-1494.	2.9	96
304	Distribution of angiographic measures of restenosis after drug-eluting stent implantation. <i>Heart</i> , 2009, 95, 1572-1578.	2.9	15
305	Migration of inferior vena cava stent into right ventricle: two- and three-dimensional echocardiographic imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2009, 10, 370-371.	1.2	1
306	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009, 30, 2714-2721.	2.2	224

#	ARTICLE	IF	CITATIONS
307	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	2.2	207
308	Prognostic Value of Kidney Function in Patients With ST-Elevation and Non-“ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Kidney Diseases</i> , 2009, 54, 830-839.	1.9	25
309	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	2.9	20
310	Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 291-299.	2.9	156
311	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2009, 409, 46-51.	1.1	8
312	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , 2009, 157, 620-624.e2.	2.7	91
313	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1760-1768.	2.8	180
314	Drug-Eluting Stents in Percutaneous Coronary Intervention. <i>Drug Safety</i> , 2009, 32, 749-770.	3.2	63
315	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. <i>Cardiology</i> , 2009, 113, 198-206.	1.4	36
316	Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Clinical Science</i> , 2009, 116, 651-658.	4.3	22
317	Polymer coatings and delayed arterial healing following drug-eluting stent implantation. <i>Minerva Cardioangiologica</i> , 2009, 57, 567-84.	1.2	87
318	Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 944-949.	1.7	8
319	Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. <i>Journal of Internal Medicine</i> , 2008, 264, 472-480.	6.0	82
320	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 512-517.	2.8	69
321	A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1584-1588.	2.8	904
322	Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. <i>European Heart Journal</i> , 2008, 29, 1418-1423.	2.2	81
323	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. <i>European Heart Journal</i> , 2008, 29, 2868-2876.	2.2	92
324	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 290-296.	2.2	51

#	ARTICLE	IF	CITATIONS
325	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. European Heart Journal, 2008, 29, 1975-1982.	2.2	182
326	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. European Heart Journal, 2008, 30, 923-931.	2.2	123
327	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine, 2008, 359, 688-696.	27.0	323